Topical Veterinary Composition Crystallization Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Liquid veterinary compositions containing high concentrations of fipronil and permethrin tend to crystallize on animal coats during application, leading to reduced therapeutic efficacy and environmental contamination.
Innovation Solution
Incorporating pyriproxyfen at a concentration of between 1% and 10% by weight/volume into the composition prevents crystallization of fipronil and permethrin, maintaining the solution's clarity and stability during storage and application.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high concentrations of fipronil and permethrin (greater than 50% by weight/volume) are used in the veterinary composition, then the therapeutic efficacy against parasites is improved, but the formulation crystallizes on the animal's coat during application
Solution Approach 1:
Pyriproxyfen serves as a crystallization inhibitor that mediates between the high-concentration active ingredients (fipronil and permethrin) and the formulation vehicle. It prevents the active ingredients from crystallizing on the animal's coat while allowing them to remain at therapeutically effective concentrations greater than 50% by weight/volume in the liquid formulation.
2Adaptability or versatility
If high concentrations of fipronil and permethrin are used, then the spectrum of action against multiple parasites is broadened, but the formulation becomes unstable and crystallizes during storage and application
Solution Approach 1:
Pyriproxyfen acts as an intermediary substance that enables the formulation to maintain high concentrations of multiple active ingredients (fipronil and permethrin) with complementary spectra of action, while preventing crystallization during both storage and application, thus maintaining both versatility and stability.
Solution Approach 2:
The formulation combines multiple active ingredients (fipronil, permethrin, and pyriproxyfen) in a composite liquid system where each component contributes different properties: fipronil and permethrin provide broad parasiticidal activity while pyriproxyfen provides crystallization inhibition, creating a stable multi-functional formulation.
3Reliability
If crystallization occurs on the animal's coat, then the active material can detach due to animal movements and rubbing, but using lower concentrations to prevent crystallization reduces therapeutic action
Solution Approach 1:
Pyriproxyfen mediates the interaction between the high-concentration active ingredients and the formulation vehicle, preventing crystallization on the animal's coat. This ensures that the active material remains dissolved and adherent during animal movements and rubbing, maintaining therapeutic action without requiring concentration reduction.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The addition of pyriproxyfen inhibits crystallization, ensuring a clear, effective, and stable topical application that prevents visible crystals on the animal's coat, maintaining therapeutic action and reducing environmental contamination.
Implementation Method 1
Incorporating pyriproxyfen at a concentration of between 1% and 10% by weight/volume into the composition prevents crystallization of fipronil and permethrin
Data Source
AI summary
The present invention relates to a liquid topical veterinary pharmaceutical composition consisting of fipronil, permethrin at high concentration and pyriproxyfen such that it does not crystallize when it is applied to the coat of an animal, and to the use thereof in the prevention and/or treatment of infestations of domestic animals by external parasites. The present invention also relates to the use of pyriproxyfen as an inhibitor of the crystallization of a liquid formulation comprising fipronil and permethrin at high concentration.